OS Therapies Incorporated (OSTX) - Long-Term Debt to Capital

OS Therapies Incorporated (OSTX) is a biotech startup spending capital on R&D without generating operating revenue. Management focuses on immunotherapy for rare pediatric cancers, while the strategy relies on clinical trials and the search for venture partners. The long-term debt-to-equity history provided by the GURU.Markets system confirms this data, where the value 0.00 describes the current level of debt load.

This ratio is calculated as the relationship between liabilities with a maturity of more than one year and the amount of equity. The metric determines the business's degree of dependence on external long-term financing amid volatile rates. For OS Therapies Incorporated (OSTX), whose value depends on clinical test outcomes, this parameter reflects financial stability independent of macroeconomic influence. The GURU.Markets toolkit allows for the monitoring of excessive debt load risk through the ratio of long-term credit funds to equity. The stability of this indicator confirms the company's ability to complete research without critical overpayments.